Company Outline
Company Outline
| Company Name | Zeria Pharmaceutical Co., Ltd. (Zeria Shinyaku Kogyo K.K.) |
| Headquarters | 10-11, Nihonbashi Kobuna-cho, Chuo-ku, Tokyo 103-8351, Japan Tel. +81-3-3663-2351 |
| Established | December 1955 |
| Representative | President & COO Mitsuhiro Ibe |
| Business Operations | 1) Manufacture, sales, import and export of pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals and reagents; 2) Manufacture, sales, import and export of cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, measuring equipment, analytical equipment; and 3) Activities related to the items described in 1) and 2) |
| Paid-in Capital | ¥6,593,398,500 |
| No. of Employees | 1,777 (Consolidated, as of Mar 31, 2024) |
Executives
Board of Directors and Auditors
| Chairman & CEO | Sachiaki Ibe |
| President & COO | Mitsuhiro Ibe |
| Directors of the Board(Outside) | Tetsuo Komori |
| Kikuo Nomoto | |
| Seiji Morimoto | |
| Directors of the Board & Managing Executive Officers |
Yuuki Okazawa |
| Audit & Supervisory Board Members(Full-time) | Hirokazu Endo |
| Hiroyuki Kuroda | |
| Audit & Supervisory Board Members(Outside) | Yukiko Naka |
| Masaru Kamisuki |
Executive Officers
| Managing Executive Officers | Hiroki Kato |
| Executive Officers | Yoshihiro Hiraga |
| Toshiaki Kawagoe | |
| Kenji Kusano | |
| Mitsuru Iwai | |
| Kazuhiro Akiba | |
| Kenichi Suzuki | |
| Masakazu Sakurai | |
| Yasuhisa Tanaka |
Company History
| 1955.12 | Zeria Yakusho Kenkyusho Co., Ltd. was established in Tokyo (capital: ¥3 million). |
| 1959.11 | Launched Chondroitin, a pharmaceutical product. |
| 1964.12 | Launched Chondroitin ZS Tablets, a remedy for arthralgia and lumbalgia. |
| 1968 | Launched Hepalyse Tablets. |
| 1970.5 | Changed name to Zeria Pharmaceutical Co., Ltd. |
| 1975.4 | Saitama Plant started operations. |
| 1979.3 | Launched New Hepalyse, a nutrient tonic for physical fatigue and exhaustion. |
| 1983.10 | Established Central Research Laboratories in Saitama. |
| 1986.4 | Developed and launched Avitene, an absorbable topical hemostat in-licensed from U.S.-based Alcon Laboratories, Inc. |
| 1987.11 | Launched WithOne, an herbal laxative. |
| 1988.11 | Tsukuba Plant started operations. |
| 1990.9 | Launched Acinon Capsules 150, an anti-ulcerant in-licensed from U.S.-based Eli Lilly and Company and co-developed with Eli Lilly Japan K.K. |
| 1991.9 | Launched Ancer 20 Injection, an anti-leukopenia after radiotherapy. |
| 1993.9 | Launched Peon Tablets 80, an oral non-steroidal anti-inflammatory co-developed with Nippon Chemiphar Co., Ltd. |
| 1994.4 | Launched Landel Tablets 10/20, a long-acting calcium channel blocker co-developed with Nissan Chemical Industries, Ltd. |
| 1994.10 | Launched Promac Granules 15%, a zinc containing anti-ulcerant. |
| 1996.2 | Launched New Hepalyse Plus, a nutrient tonic for physical fatigue and exhaustion. |
| 1998.12 | On December 22, listed on the Second Section of the Tokyo Stock Exchange. Introduced new company logo and symbol mark. |
| 1999.2 | Started a new distribution system outsourced to ITOCHU Corporation and its affiliate, Superlex Co., Ltd. |
| 2000.3 | On March 1, listed on the First Section of the Tokyo Stock Exchange. |
| 2004.1 | Concluded a licensing agreement with Tillotts Pharma AG in Switzerland for the development, manufacturing and marketing rights to Asacol for IBD in Japan. |
| 2005.7 | Launched New Hepalyse Drink, a nutrient tonic for physical fatigue and exhaustion. |
| 2006.3 | Sales of Chondroitin range of products reached ¥5 billion. |
| 2006.7 | Launched Promac D Tablets 75, a zinc containing anti-ulcerant. |
| 2006.11 | Expanded Tsukuba Plant (second phase construction). |
| 2007.6 | Launched Visiclear Tablets, an oral bowel cleansing agent for colonoscopy. |
| 2007.11 | Launched Acinon Tablets 75mg and 150mg, an H2 receptor antagonist. |
| 2008.6 | TV advertisements for Chondroitin ZS Tablets started. |
| 2008.10 | Acquired IONA INTERNATIONAL CORPORATION and made it a wholly owned subsidiary. |
| 2009.9 | Acquired Tillotts Pharma AG and made it a wholly owned subsidiary. |
| 2009.12 | Launched Asacol Tablets 400mg, a therapeutic agent for ulcerative colitis. |
| 2010.7 | TV advertisements for New Hepalyse Drink started. |
| 2010.9 | Acquired ZPD (formerly Biofac Esbjerg A/S) and made it a subsidiary. |
| 2011.11 | Launched Hepalyse W as a beverage in the general foods category for convenience stores. |
| 2012.1 | Launched New WithOne, an herbal laxative. |
| 2012.3 | TV advertisements for New WithOne started. |
| 2013.3 | Launched Phosribbon Combination Granules, a therapeutic agent for hypophosphatemia. |
| 2013.6 | Launched Acofide Tablets 100mg, a therapeutic agent for functional dyspepsia. |
| 2013.10 | Launched Hepalyse W Hyper as a beverage in the general foods category for convenience stores. |
| 2014.9 | Launched Prefemin, a therapeutic agent for PMS |
| 2015.6 | Launched Hepalyse W Sparkling as a carbonated nutritional drink in the general foods category for convenience stores. |
| 2015.7 | Tillotts Pharma AG acquired all global rights outside the United States for Entocort from AstraZeneca. |
| 2015.9 | Acquired 49% of the shares of Pharmaceutical Joint Stock Company of February 3rd and made it a subsidiary. |
| 2016.3 | Launched Hepalyse W Premium as a beverage in the general foods category for convenience stores. |
| 2016.3 | Sales of Hepalyse range of products reached ¥10 billion. |
| 2018.4 | Launched Hepalyse W Premium KIWAMI as a beverage in the general foods category for convenience stores. |
| 2020.4 | Acquired Kenso-Seiyaku (former Nissui Pharma Medical Sales) and made it a subsidiary. |
| 2020.9 | Launched Ferinject solution for injection/infusion 500mg, a therapeutic agent for Iron deficiency anemia. |
| 2020.11 | Tillotts Pharma AG has acquired the rights to DIFICLIR (fidaxomicin) from Astellas Pharma Europe Ltd for Europe, Middle East, Africa and selected CIS. |
| 2021.12 | Launched Belfemin, a medicine to improve leg swelling caused by mild venous insufficiency. |
| 2022.03 | Launched Colpermin, a medicine to improve irritable bowel syndrome(IBS). |
| 2022.04 | The listing has been transferred from the First Section to the Prime Market of the Tokyo Stock Exchange as a result of a review of the market segmentation. |
| 2023.04 | Zeria Pharmaceutical has taken over from Astellas Pharma the manufacturing and marketing approval for Dafclear Tablets 200 mg (generic name: Fidaxomicin), a treatment for infectious enteritis caused by Clostridioides (Clostridium) difficile. |